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1. Introduction 
Toxicological screening using animals are necessary for drug development registration. This 
approach is time-consuming, costly, labour intensive, stressful for the animals and 
susceptible to inaccuracies due to individual differences between animals. So, the screening 
of candidate chemicals in early development is often replaced with in vitro cell culture 
systems (Pearson, 1986; Liebsch & Spielmann, 2002). In vitro studies using cell lines were 
capable of providing more rapid, precise, relevant information than some animal studies, 
and economical approach for the evaluation of the pharmaco-toxicological profiling of target 
drugs, characterised by a low compound requirement and short duration (Pearson, 1986; 
Kari et al., 2007). Also, it is possible to include mechanistic studies, and to test for toxicity 
that is specific to humans: sensitivity differences between humans and rodents can affect 
animals (Kari et al., 2007). Among the in vitro screening systems, primary cell cultures 
and/or target organ-specific cell lines can be used to measure the general toxicity of a test 
compound (Zhou et al., 2006).  
However, the sensitivity of hepatotoxicity using primary human hepatocytes or the HepG2 
cell line cannot predict effects in early development and toxicological differences, which 
depend on the state of differentiation in hepatocytes (Knasmuller et al., 2004; Xu et al., 2004). 
In addition to, primary cells such as hepatocytes in particular and many transformed human 
hepatocyte-derived cell lines (immortalized cultures, i.e Fa2-N4 cells, HepaRG cells) have 
limitations in their life span and can have donor-dependent variations (Mills et al., 2004). 
Also, they have disadvantages such as discontinuous phenotypic characteristics, functional 
properties and genetic instability. Therefore, more promised future is waiting for 
hepatocyte-like cells as the source of hepatocytes regarding the approach of stem cells use in 
the high throughput testing (Duret et al., 2007).  
Stem cells are defined functionally as cells that have the capacity to self-renew as well as the 
ability to generate differentiated cells that specialized functions in specific tissues and make 
up the organ (Thomson et al., 1998; Zhang & Wang, 2008; Schnerch et al., 2010). The 
classification of stem cells divided into embryonic stem cells (ESCs) and adult stem cells 
(ASCs) according to derivative origins. ESCs, which are derived from the inner cell mass of 
blastocysts after fertilization, can unlimited self-renewal and have pluripotent could be rise 
to cells derived from all three germ lineages. Otherwise, ASCs derived from the specialized 
cell types of the tissue from which are originated have limited self-replicate and mutilpotent 
could be giving rise to specialized cells into multiple-lineages not all three germ lineages. 
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Since Thomson and colleagues were firstly reported to potentials for therapeutic and drug 
discovery using embryonic stem cells derived from inner cell mass of human blastocysts in 
1998, stem cell research have been spotlighted more public and professional interest than 
other subject in biology field (Thomson et al., 1998; Fuh & Brinton, 2009; Astori et al., 2010; 
Rashid et al., 2010).  
Although the field of stem cell research has grown rapidly, there are focused on the cell 
therapy using stem cells in regenerative medicine because stem cells have a great fascinating 
potential could be differentiation into the specialized cells to replace damaged cells or tissues. 
ESCs is an attractive source for cell therapy, however, there are several obstacles including 
ethical problems to clinical application using ESCs in degenerative medicine. Especially, the 
optimal guideline for differentiation of ESCs have been shown to be controversy in the 
condition of differentiation into target cells due to various factors used to induce the 
differentiation in ESCs (Denham & Dottori, 2009; Zagami et al., 2009; Bourzac et al., 2010).  
Due to the reason, many scientists have been found a research field to make the best use of 
the potential benefits of stem cells. Stem cell-based systems have striking advantages to 
select of lead candidates and development of new therapeutic drugs because their 
proliferation ability and plasticity to generate several cell types. In addition, it is possible to 
analyze effects or toxicities of target drugs according to differentiation steps from immature 
to mature cells could be function. In vitro assaying of embryotoxicity using embryonic stem 
cells for the early determination of the teratogenic potential of a compound have been 
attempted (Kim et al., 2006; Kulkarni & Khanna, 2006). Also, in vitro screening system using 
mouse embryonic stem cells have been suggested by the European Center for Validation of 
Alternative Methods (ECVAM) committee (Spielmann et al., 2001; Genschow et al., 2002). 
Therefore, drug screening system using stem cells is a large range of opinion on this issue. 
The application of ESCs in drug screening is a promising, innovative alternative that 
appears to have early efficacy, while reducing the adverse outcomes at later stages of 
development. Furthermore, it is very sensitive in toxicity screening, as compared to other cell 
lines. For this reason, the application of ESCs could be an important new tool for developing a 
unique in vitro model with the potential to predict genotoxicity in humans. Drug screening 
using ESCs focuses on reproductive biology and embryo development. The embryonic stem 
cell test (ESCT) can detect developmental abnormalities such as abnormal embryogenesis and 
malformations caused by mutagenic or embryotoxic substances in early embryogenesis. 
With this intention, this chapter review outlines the limitation of traditional toxicity 
screening including in vitro and in vivo screening system. This brief review outlines the 
construction of more efficient mouse ESC-derived embryoid bodies (EBs) for use as a 
vasculogenesis model and as a tool for screening the cytotoxicity of new compounds, and 
the cytotoxicity of 5-fluorouracil (5-FU), and to examine its effects on cell viability, 
proliferation, and differentiation in mouse ESC-derived endothelial differentiation. Also, we 
also consider the obstacles that need to be overcome to make the embryonic stem cells cost-
effective, to enable guided differentiation to target cells, and to establish a reproducible in 
vitro assay to increase its efficacy as a screening system. Finally, we introduce the latest 
research on the ESCT and the potential of using ESCs for drug screening. 
2. Characterization of embryonic stem cells  
Stem cells have the capacity to self-renew as well as the ability to generate differentiated 
cells that specialized functions in specific tissues and make up the organ. The classification 
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of stem cells divided into embryonic stem cells (ESCs) and adult stem cells (ASCs) according 
to derivative origins. ESCs, which are derived from the inner cell mass of blastocysts after 
fertilization, can unlimited self-renewal and have pluripotent could be rise to cells derived 
from all three germ lineages. Otherwise, ASCs derived from the specialized cell types of the 
tissue from which are originated have limited self-replicate and mutilpotent could be giving 
rise to specialized cells into multiple-lineages not all three germ lineages.  
Since mouse embryonic stem cells (mESCs) and human embryonic stem cells (ESCs) were 
established in 1981 and in 1998, ESCs are a hot issue in stem cell research (Martin, 1981; 
Thomson et al., 1998). Especially, unique characterization of human ESCs shows unlimited 
proliferation activity through the expression of stemness markers such as Oct-4, alkaline 
phospatase, Nanog, SSEA-4, TRA-1-60, and TRA—81 in condition of co-cultured with feeder 
cells (Figure 1).  
 
 
 
Fig. 1. Characterization of human embryonic stem cells. Morphology of human ES cells 
cultured with feeder cells (A) and embryonic body (B), Expression of stemness markers, 
Alkaline phosphatase (C), Oct-4 (D), SSEA-1 (E), SSEA-4 (F), TRA-1-60 (G), and TRA-1-80 
Also, human ESCs in vitro can be expanded indefinitely in the undifferentiated state and 
still retain the capacity for differentiation into endodermal, mesodermal, and ectodemal 
lineages cells under specific condition in vitro. The potential for differentiation of human 
ESCs could be confirmed by teratoma formation in SCID mice transplanted human ESCs. 
Teratoma is an encapsulated benign tumor with tissues or organ components resembling 
normal derivatives of all three germ layers (Figure 2). The potentials offer a therapeutic 
intervention in the treatment of degenerative diseases that affect various tissues and their 
therapeutic effects may be influenced by numerous factors such as cell count, differentiation 
potential, transplant method, and disease model (Petersen et al., 1999; Huttmann et al., 2003; 
Kuo et al., 2008). 
The characterization of human ESCs derived from early embryos that seem to share many of 
the properties of mouse ESCs has refocused attention on the in vitro properties of ESCs 
(Thomson et al., 1998). Therefore, mouse and human ESCs will provide new insights into 
embryonic development as well as its translation into therapeutic outcomes.  
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Fig. 2. Differentiation potential of human ESCs by teratoma formation in SCID mice 
engrafted human ESCs. Teratoma showing tissues from all three germ layers; endoderm 
(gut epithelium, A), mesoderm (cartilage, B), and ectoderm (neural rosettes, C)    
3. Limitation of traditional toxicity screening  
Toxicogenomics, which combines toxicology and genomics, is a scientific field that studies 
how the gene and protein activity within particular cell or tissues of an organism is involved 
in responses to toxicants. Also, they studies for genetics, mRNA expression, cell and tissue-
wide protein expression and metabolomics to understand the role of gene-toxicants 
interactions in disease. From these processing, new biomarkers for toxicity can discover as 
well as predictive in toxicology. However, the relationship between dose and its effects on 
the exposed organism still controversy because there are several factors including age, sex, 
individual variability, and species differences affected susceptibility and variability in 
toxicology.  
Toxicological screening using animals are necessary for drug development registration. 
Although there are several animal models from zebra fish to monkey for in vivo toxicity 
screening as well as drug development, however, there are many kinds of considerations in 
vivo toxicity screening using animal model. Especially, embryotoxicity tests using animals 
are a traditional strategy to identify potentially hazardous chemicals. They can also be used 
to confirm the absence of toxic properties in the development of potentially useful new 
substances (Spielmann, 2009). Because this approach is time-consuming, costly, labour 
intensive, stressful for the animals and susceptible to inaccuracies due to individual 
differences between animals, the screening of candidate chemicals in early development is 
often replaced with in vitro cell culture systems (Pearson, 1986; Liebsch & Spielmann, 2002; 
Bremer & Hartung, 2004; Knight, 2007). Animal ethics in vivo screening system have been 
becoming emphasized by Institutional Animal Care and Use Committees (IACUC). In 
addition, it is difficult to check the correct time point for toxicity testing in screening using 
animal model. Therefore, there is a need for alternative methods to evaluate the potential 
reproductive toxicity of chemical substances, by in vitro systems. To develop a new 
alternative screening test, many scientists have tried to use cell lines, primary cell cultures of 
dissociated cells from mice or rat embryo limb buds, midbrains for micromass tests, or 
whole embryos from rat (Steele et al., 1983).  
In vitro studies using cell lines were capable, or potentially capable, of providing more rapid, 
precise, relevant information than some animal studies, and economical approach for the 
evaluation of the pharmaco-toxicological profiling of target drugs, characterised by a low 
compound requirement and short duration (Pearson, 1986; Kari et al., 2007). Also, it is 
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possible to include mechanistic studies, and to test for toxicity that is specific to humans: 
sensitivity differences between humans and rodents can affect animals (Kari et al., 2007). 
Among the in vitro screening systems, primary cell cultures and/or target organ-specific cell 
lines can be used to measure the general toxicity of a test compound (Zhou et al., 2006). 
However, the sensitivity of hepatotoxicity using primary human hepatocytes or the HepG2 
cell line cannot predict effects in early development and toxicological differences, which 
depend on the state of differentiation in hepatocytes (Knasmuller et al., 2004; Xu et al., 2004). 
In addition to, primary cells such as hepatocytes in particular and many transformed human 
hepatocyte-derived cell lines (immortalized cultures, i.e Fa2-N4 cells, HepaRG cells) have 
limitations in their life span and can have donor-dependent variations (Mills et al., 2004). 
However, they have disadvantages such as discontinuous phenotypic characteristics, 
functional properties and genetic instability.  
In toxicological research, the development of alternative in vitro toxicity screening systems 
to replace in vivo screening methods using animal experiments and conventional screening 
systems is important. Although applications using primary cells derived from rodent 
embryo or tissue-specific cell lines originating from humans have been tried, the validation 
of cytotoxicity during cellular biological processing must be improved in order to establish 
new and alternative in vitro screening methods, and to increase the efficiency of toxicological 
analysis through these methods (Tiffany-Castiglioni et al., 1999). Therefore, more promised 
future is waiting for hepatocyte-like cells as the source of hepatocytes regarding the 
approach of stem cells use in the high throughput testing (Duret et al., 2007).  
4. In vitro toxicity screening using embryonic stem cells 
Embryonic stem cells are generally obtained from inner cells mass in blastocysts of either mice 
or humans. Especially, drug or toxicity screening using human ESCs have many advantages 
over primary cells and immortalized cell lines for in vitro toxicity screening, including unique 
properties such as unlimited self-renewal, plasticity to generate various cell types and 
availability of cells of human origin (Davila et al., 2004; Kulkarni & Khanna, 2006; Zhang & 
Wang, 2008).  However, there are some disadvantages as they do not grow as well and are 
more difficult to cultivation than mouse ESCs. Also, the stem cell technologies for directing 
them to differentiate are less defined than those for mouse ESCs and it is necessary to provide 
human ESCs that can be employed in a practical manner for compound screening. 
Due to the reason, an Embryonic Stem Cell Test (EST), which mirrors growth and 
differentiation, is an in vitro test system well-suited for the evaluation of the embryotoxic 
potential of substances (Evans & Kaufman, 1981; Martin, 1981; Smith, 1992; Spielmann et al., 
1997; Ramalho-Santos et al., 2002; Wobus & Boheler, 2005). The regulation of the 
differentiation of mouse ES cells is controlled by critical transcription factors, such as STAT3 
(Niwa et al., 1998), Oct4 (Nichols et al., 1998), and Nanog (Chambers et al., 2003): Previous 
studies have shown that embryonic stem (ES) cells require the expressions of different 
transcription factors to specify the stem cell state, and that these contribute to the generation 
of entirely different lineages on changing culture conditions and altering the expression 
levels of Oct4, a key determinant of the pluripotency for in vitro systems (Wobus & Boheler, 
2005). In addition, these mES cell systems were reported to be very useful for measuring 
embryotoxicity (Seiler et al., 2004). Moreover, mouse embryonic stem cells can be routinely 
employed to screen chemical compounds for teratogenic effects (Scholz et al., 1999; 
Rohwedel et al., 2001; Vanparys, 2002).  
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In this chapter, we introduce the possibility of endothelial-like cells derived from mouse 
embryonic bodies as an in vitro vasculogenesis model and the usefulness of mouse ESCs for 
in vitro toxicity screening for 5-fluorouracil (5-FU), anti-angiogenesis agents.  
5. Endothelial-like cells derived from mouse embryonic bodies as an in vitro 
vasculogenesis model 
The formation of new blood vessels (vasculogenesis) during embryonic development is an 
important basic step. This process involves the differentiation of angioblasts from mesoderm 
during the early developmental stages and their organization from a primitive vascular 
network (Vittet et al., 1996), and is characterized by the expression of endothelial cell 
specific molecules during the formation of vascular structures in ES-derived embryoid 
bodies (EBs). A number of markers including vascular endothelial growth factor receptors-2 
(Flk-1) (Yamaguchi et al., 1993), platelet endothelial cell adhesion molecule (PECAM) 
(Redick & Bautch, 1999), and vascular endothelial (VE) cadherin as markers of 
vasculogenesis have been reported (Dejana et al., 1999). Endothelial, endothelial-like cells, 
and endothelial precursor cells (EPCs) derived from stem cells have been explored to 
establish a toxicity screening system for endothelial-specific toxicants (Kim & von Recum, 
2008). The feasibility of these screening systems depends on the differentiation processes of 
the ESCs used; guided differentiation into target cell types and accurate investigation of the 
mechanisms of endothelial toxicity are necessary. Recently, we reported that endothelial-like 
and endothelial cells derived from mouse ESCs using EGM medium and optimal protocols 
are more sensitive to 5-FU toxicity than undifferentiated endothelial cells as well as a mouse 
endothelial cell line (Kim & von Recum, 2008).  
Doetschman et al (1985) were the first to show an in vitro mouse model based on the 
differentiated ES cells. When mES cells are grown in the absence of feeder cells and myeloid 
leukaemia inhibitory factor (LIF), they are able to differentiate spontaneously (Doetschman 
et al., 1985). EBs were formed by spheroid aggregation during post-implantation in 
embryonic tissues and maintained in conditioned medium containing a cocktail of vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukin-6 (IL-6) 
and erythropoietin (EPO) in 1% methylcellulose to induce the formation of EBs (Wang et al., 
1992; Vittet et al., 1996). This model system, which forms a primitive vascular plexus, 
provides an attractive tool for investigating the mechanisms involved in vasculogenesis, i.e., 
angioblast differentiation, proliferation, migration, endothelial cell-cell adhesion, and 
vascular morphogenesis (Doetschman et al., 1985; Risau et al., 1988; Wang et al., 1992). In 
addition, co-cultures with stromal cells, even adherent monolayer cultures in the absence of 
LIF (Ying et al., 2003), have been used to differentiate mES cells in vitro. Moreover, the 
expression levels of markers of endothelial differentiation at the mRNA and protein levels 
differ according to endothelial cell differentiation and culture conditions (Doetschman et al., 
1985; Risau et al., 1988; Vittet et al., 1996). For these reasons, the mechanism of endothelial 
cell differentiation involved in the regulation of vasculogenesis remains unclear. However, 
the exact molecular biological role of 5-FU on cell cycle regulation in the endothelial 
differentiation of mouse ESCs has not been fully explained yet.  
Therefore, we demonstrated that the population of endothelial cells derived from mES cells 
and to apply this as a tool for the screening of agents with vascular developmental toxicity. 
Also, we investigated that the specific action of 5-FU on the endothelial differentiation of 
cells derived from mouse ESCs, finally, we demonstrated that the correlation between cell 
cycle regulation and endothelial differentiation in mouse ESCs exposed by 5-FU. 
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5.1 Materials and methods 
5.1.1 Cell line and culture conditions  
Mouse D3 ES cells (ATCC Cat. No. CRL-1934, Rockville, MD, USA) were co-cultured with 
mitomycin C-treated mouse embryonic fibroblast (MEF) cells in high glucose DMEM 
(Gibco-BRL, Invitrogen, Carlsbad, CA) containing 15% fetal bovine serum (FBS; Hyclone, 
Ogden, UT), 1000 U/ ml of LIF/ESGRO (Chemicon, Temecula, CA), and basic ES medium 
components [50 U/ml of penicillin and 50 μg/ml streptomycin (Gibco-BRL, Invitrogen, 
Carlsbad, CA), 1% non-essential amino acids (Gibco-BRL, Invitrogen, Carlsbad, CA) and 0.1 
mM β-mercaptoethanol (Gibco-BRL, Invitrogen, Carlsbad, CA)]. Mouse endothelial cells 
(C166) (ATCC Cat. No. CRL-2581, Rockville, MD), used as a control for toxicity testing, were 
cultured in endothelial cell basal medium-2 (EBM-2) containing 5% FBS and cytokine 
cocktail. The hanging drops method (20 μl per drop; 1x105 cells ml-1) was used to induced 
differentiation as described by Heuer and colleagues (Heuer et al., 1993) with minor 
modifications. After incubation for 3 more days, EBs were transferred to gelatin-coated 
wells of Chamber slides (Nunc, Denmark) or 60mm dishes to allow attachment. To promote 
endothelial cell differentiation, 3-day-old EBs were placed in DMEM containing 10% FBS 
and medium consisting of EBM-2, 5% FBS, growth factor cocktail, and ascorbic acid (EGM2-
MV Bullet Kit; Clonetics/BioWhittaker, Walkersville, MD).  
5.1.2 Cell viability and proliferation analysis 
The viability and proliferative activity of ES cells were analyzed using the 3-(4,5-
dimethylthiazol-2yl)-2,5,-diphenyl tetrazolium bromide (MTT) assay and by 5-bromo-2’-
deoxyuridine (BrdU) incorporation for 10 days, respectively. For the MTT assay, mEBs were 
hanging drop cultured for 2 days and then grown in standard culture medium (DMEM 
containing 10% FBS) for 24 hours to allow attachment. 20 μl of MTT (5mg/ml) was then 
added to 200 μl of the culture medium on days 3, 4, 6, 8, and 10, followed by incubation at 
37°C for 4 hr. After incubation, the MTT solution was carefully removed and 150 μl of 
DMSO (Sigma, St Louis, MO) was added to each well. The plates were then shaken on a 
plate mixer until the crystals dissolved. The absorbance of the resulting colored solution was 
measured at 570 nm in a Genios luminometer (TECAN, Austria) at a reference wavelength 
of 630nm. BrdU detection kits (Roche Molecular Biochemicals, Indianapolis, IN) were used 
to measure BrdU incorporation. For BrdU assays, mEBs were hanging drop cultured for 2 
days and then grown in standard culture medium (DMEM containing 10% FBS) for 24 hours 
to allow attachment. On days 3, 4, 6, 8, and 10, 10 μl of 100 μM BrdU was added to each 
well, and the cells were incubated for 4 h. After removing the medium, the cells were fixed 
and DNA was denatured using FixDenat reagent (Roche Applied Sciences) for 30 min. The 
reagent was then removed, anti-BrdU-POD solution was added and the plates were 
incubated for 90 min at room temperature. The cells were then washed three times with 
washing solution, after which 100 μl of substrate solution was added and the absorbance 
was measured at 370 and 490 nm using a Genios luminometer (TECAN, Austria). 
5.1.3 RNA isolation and reverse transcription-polymerase chain reaction (RT-PCR)   
Cells were directly sorted into tubes containing Trizol (Gibco-BRL, Invitrogen, Carlsbad, 
CA) and mRNA was extracted according to the manufacturer's protocol. The isolated RNAs 
were quantified using a spectrophotometer (SmartSpec 3000, Bio-Rad). First-strand cDNA 
was synthesized from 2 µg of total RNA using an oligo (dT) primer and a SuperScript First-
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Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA), according to the 
manufacturer’s instructions. First-strand cDNAs were amplified in a final volume of 25 μl 
containing 0.5 U Taq DNA polymerase (TaKaRa Biotechnology, Korea) and 10 pmol of each 
target primer. PCR conditions were as follows: 5 minutes at 94°C, 30 amplification cycles 
(denaturation at 94°C for 1 minute, annealing at 55°C or 60°C for 1 minute, and extension at 
72°C for 1 minute), followed by a final extension at 72°C for 5 minutes. The PCR primers 
and the size of the amplified products are shown in Table 1. The amplified products were 
separated on 1.5% agarose gels and visualized by ethidium bromide staining. cDNA 
samples were adjusted to yield equal GAPDH amplifications.  
 
Gene Sequences Size (bp) 
FLk-1 
F: 5’-CAGCTTCCAAGTGGCTAAGG-3’ 
R: 5’-CAGAGCAACACACCGAAAGA-3’
264 
PECAM 
F: 5’- GCCTGGAGAGGTTGTCAGAG-3’ 
R: 5’- GGTGCTGAGACCTGCTTTTC-3’ 
357 
VE-Cadherin
F: 5’- ACCGGATGACCAAGTACAGC-3’ 
R: 5’- TTCTGGTTTTCTGGCAGCTT-3’ 
292 
GAPDH 
F: 5’- TGTTCCTACCCCCAATGTGT-3’ 
R: 5’- TGTGAGGGAGATGCTCAGTG-3’ 
396 
Table 1. Sequences of oligonucleotide primers used for RT-PCR analysis  
5.1.4 Immunocytochemistry 
After inducing differentiation, the cells were exposed to 5-FU with/without probucol for 24 
hours and fixed with freshly prepared MeOH/DMSO (4:1) overnight at 4°C. Cells were 
blocked with blocking solution containing 1% BSA and 0.1% Tween 20 for 30 min, and then 
incubated with rabbit anti-mouse FLK-1 (1:100) (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA), rat anti-mouse PECAM (1:100) (MEC 13.3, Santa Cruz), or goat anti-mouse VE-
cadherin (1:100) (Santa Cruz), or rabbit anti-mouse PCNA (1:100) (Santa Cruze, 
Biotechnology, Inc) at 4°C overnight. After washing, cells were incubated with goat anti-
rabbit IgG-TRITC (1:100) (Chemicon, Temecula, CA), goat anti-rat IgG-FITC (1:100) (Santa 
Cruz), or donkey anti-goat IgG-FITC (1:200) (Santa Cruz) as secondary antibodies, 
respectively. Stained slides were embedded in 30% Mowiol (Calbiochem-Novabiochem, 
Schwalbach, Germany). Images were obtained and analyzed using a Bio-Rad confocal 
microscope (Radiance 2000 FCMP, Bio-Rad, USA)  
5.1.5 Flow cytometry  
Cultured cells were harvested using cell dissociation buffer (Sigma, St Louis, MO). Cells 
were resuspended at 106 cells/100 μl in suspension buffer, and then were incubated with 1 
μg/100 μl of PE anti-mouse FLK-1 (Avas 12a1, PharMingen) and FITC anti-mouse PECAM 
(MEC 13.3, PharMingen), or (FITC) rat anti-mouse VE-cadherin (11D4.1, PharMingen) for 30 
minutes at 4°C. Negative controls were incubated for 30 min at 4°C with fluorochrome-
labeled irrelevant isotype control antibodies: 1 μg/100 μl PE rat IgG2a’ (PharMingen, San 
Diego, CA), 1 μg/100μl FITC rat IgG2a’ (PharMingen), or 1 μg/ 100 μl anti-rat FITC-
conjugated IgG (Santa Cruz). In order to analyse how Oct-4 expression varies in mouse 
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ESCs through different stages of endothelial cell differentiation, endothelial differentiation 
induced cells for 0, 4, 7 and 10 days were harvested using cell dissociation buffer (Sigma, St 
Louis, MO). To analyse PCNA expression, the cells were exposed to 5-FU with/without 
probucol for 24 hours at day 9. After 24 hours incubation, control cells and treated cells were 
harvested using cell dissociation buffer (Sigma, St Louis, MO). Cells were re-suspended at 
106 cells/100 µl in suspension buffer and then incubated with 1µg/100 µl of rabbit anti-
mouse Oct-4 (Santa Cruz, Biotechnology, Inc), or rabbit anti-mouse PCNA (1:100) (Santa 
Cruze, Biotechnology, Inc) for 1 hour at 4°C. Negative controls were incubated for 1 hour at 
4°C with fluorochrome labelled irrelevant isotype control antibodies: 1 µg/ 100 µl goat anti-
rabbit FITC-conjugated IgG (Chemicon) or goat anti-rabbit IgG-TRITC (1:100) (Chemicon, 
Temecula, CA) for primary antibodies, respectively. After staining, cells were analyzed 
without fixation using a FACS Calibur flow cytometer (Becton Dickinson, MA) using 5 
μg/ml of propidium iodide (Sigma) to exclude dead cells. Data was analyzed using 
CellQuest software (Becton Dickinson, MA).  
For cell cycle analysis in differentiation into endothelial cell of mouse ESCs, the treated cells 
were trypsinised and fixed in cooled 70% ethanol at 4°C. The cells were then incubated in 
0.3 ml of DNA staining solution (100 µg/ml PI, 1 mg/ml RNase A (DNase-free) in PBS).  
The cells were then transferred into D-Hank’s solution. The cell suspension was stored on 
ice in a dark room for a minimum of 30 min and analysed within 2 hours. Data analysis was 
carried out using CellQuest software (Becton Dickinson, MA). 
5.1.6 Capillary tube formation by endothelial cells on matrigel  
To induce tube formation on matrigel, mES cells were grown in EGM-2 medium for 10 days 
and then prepared as a single-cell suspension. 5x104 ES cells were then plated on Matrigel 
(Becton Dickinson, MA), incubated at 37°C, and analyzed using a phase contrast microscope 
(Nikon, Eclipse TE 2000-U, Japan).  
5.1.7 Cytotoxicity analysis 
The cytotoxic effects of 5-Fluorouracil on mES cells and mouse endothelial cell (C166) were 
analyzed using a validated embryonic stem cell test protocol and MTT assay (Spielmann et 
al., 1997; Scholz et al., 1999). Briefly, 1000 cells were seeded into each well of a 96-well 
microtitre plate and grown in the presence of a concentration range of 5-FU and probucol. A 
negative control containing solvent diluted in medium was also included. At day 9, the cells 
were exposed to 5-FU (10 μM) with/without probucol (50 µM) in a total volume of 200 μl for 
24 hours. The 5-FU and probucol were dissolved in cell culture medium and ethanol, 
respectively. The final ethanol concentration in the wells was 0.1%. The controls were 
incubated with equal volumes of drug solvents to avoid changes that could be due to 
solvent. 20 µl of MTT (5mg/ml) was added to 200 µl culture medium on day 10, followed by 
incubation at 37°C for 4 hrs. After incubation, the MTT solution was carefully removed and 
150 μl of DMSO (Sigma, St Louis, MO) was added to each well. The plates were shaken on a 
plate mixer until all crystals had dissolved. The absorbance of the resulting coloured 
solution was measured at 570 nm with a Genios luminometer (TECAN, Austria) at a 
reference wavelength of 630nm. Cytotoxicity was expressed as a percentage of cells 
surviving, relative to untreated cultures, and the concentration required to inhibit cell 
growth by 50% (IC50) was calculated. Each experiment was performed using six replicates 
for each drug concentration and repeated in triplicate.  
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5.1.8 Microarray 
For cDNA microarray analysis, differentiated mouse ESCs treated with/without 5-FU (10 
µM) for 24 hours were collected. Their total RNA was extracted using Trizol (Gibco-BRL, 
Invitrogen, USA) and mRNA was extracted according to the manufacturer's protocol. The 
quantity and quality of total RNA and amplified RNA were assessed by using a Bioanalyzer 
2100 (Agilent Technologies). The Applied Biosystems Mouse Genome Survey Microarray 
contains 32,996 60-mer oligonucleotide probes, representing 32,181 individual mouse genes. 
Digoxigenin-UTP labelled cRNA was generated and linearly amplified from 2 µg of total 
RNA using Applied Biosystems Chemiluminescent RT-IVT Labelling Kit v.2.0 and 
manufacturer’s protocol (Applied Biosystems). Array hybridization (five arrays per sample), 
chemiluminescence detection, image acquisition and analysis were performed using 
Applied Biosystems Chemiluminescence Detection Kit (Applied Biosystems) and Applied 
Biosystems 1700 Chemiluminescent Microarray Analyzer (Applied Biosystems), following 
the manufacturer's protocol. Images were auto-gridded, then spot and spatially normalised. 
Chemiluminescent signals were quantified, corrected for background, and the final images 
and feature data were processed using the Applied Biosystems 1700 Chemiluminescent 
Microarray Analyzer software v1.1. Data and images were collected through an automated 
process for each microarray using the 1700 analyzer. A total of 10 arrays were run for the 
two groups (five technical replicates for each group). A global median normalisation, which 
normalises signal intensities across all microarrays to achieve the same median signal 
intensities for each array, was performed on the Applied Biosystems data sets. For Applied 
Biosystems arrays, the detection threshold was set as S/N > 3 with a quality flag < 100. 
Correlation and coefficient of variation (CV) analyses were performed using Matlab® 
software (Mathworks, Natick, MA). Differential expression analysis was done using two 
different statistical methods: (1) ANOVA analysis was performed using Avadis software. 
Differentially expressed genes between control and 5-FU (10 µM) treated groups were 
determined based on the following criteria: (a) p < 0.001 in ANOVA analysis; (b) average 
change between control and 5-FU (10 µM) treated groups > 2 fold; (c) detectable in more 
than 50% samples. (2) Significance Analysis of Microarray (SAM: http://www-
stat.stanford.edu/ tibs/SAM), a supervised learning statistical software that performs a 
modified t-test to identify genes with significant changes in expression, and uses 
permutations to estimate the false discovery rate (FDR). Hierarchical clustering of log ratios 
was performed using the software (http://rana.lbl.gov/EissenSoftware.htm) Cluster and 
Treeview; Euclidean correlation, median centring and complete linkage were applied in all 
clustering applications.  
5.1.9 Western blot analysis 
Control cells and treated Cells were lysed in RIPA buffer (1% NP-40, 150 mM NaCl, 0.05% 
DOC, 1% SDS, 50 mM Tris) containing protease inhibitor for 1 h at 4°C. The supernatant was 
separated by centrifugation, and protein concentration was determined with a Bradford 
protein assay kit II (Bio-rad). Proteins (25 μg/well) denatured with Laemmli sample buffer 
(Sigma) were separated by 10% SDS-polyacrylamide gel (Bio-Rad) under a constant current 
of 50 mV. Proteins were transferred onto nitrocellulose membranes (0.45 mm, Amersham 
Life Sciences). The membranes were blocked with a 5% BSA solution for 3 hrs, washed with 
PBS containing 0.2% Tween 20, then incubated with the primary antibody overnight at 4°C. 
Human specific antibodies against CDK-2, CDK-4, Cyclin D1, Cyclin E, p21WAF1/CIP1,  
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p27 Kip1, p53, and β-actin from Santa Cruz Biotechnology (Santa Cruz Biotechnology) were 
used to probe the separate membranes. The immunoreaction was continued with the 
secondary goat anti-rabbit horseradish-peroxidase conjugated antibody after washing for 2 
hours at room temperature. The specific protein bands were detected by enhanced 
chemiluminescence (Pierce), with X-Omat AR films (Kodak). As a protein loading control, 
parallel gels were subjected to Western blot analysis using a β-actin antibody (Santa Cruz 
Biotechnology). 
5.1.10 Statistical analysis 
All results are expressed as percentages of untreated control values or as the means ± SD of 
three independent experiments, each with six replicates. Statistical significance was 
determined using the Student’s t-test for paired data. A P value of < 0.05 was regarded as 
significant, and IC50 values were calculated using Sigmaplot version 9.0. 
5.2 Results 
5.2.1 Expressions of endothelial markers at the mRNA and protein levels during the 
early stages of differentiation   
We analyzed the mRNA expression levels of endothelial markers, i.e., FLK-1, PECAM, and 
VE-Cadherin, during different culture conditions and differentiation stages within 7 days of 
plating embryoid bodies by RT-PCR (Figure 3A). In case of the expression of the FLK-1 
gene, no difference was found between DMEM containing FBS and EGM-2 media.  
 
 
Fig. 3. Expression patterns of endothelial cell-specific markers at the mRNA and protein 
levels in mES-derived embryoid bodies. Gene expression in ES-derived EBs by RT-PCR (A). 
Expressions of FLK-1, PECAM, and VE-cadherin in differentiated mES cells at day 10 by 
immunofluorescence (B) (× 40) 
However, the expressions of PECAM and VE-Cadherin mRNA were higher in EGM-2 than 
in DMEM containing FBS, and their expressions in EGM-2 medium were higher during the 
early stages. Expression of endothelial cell differentiation markers at the mRNA and protein 
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levels were similar with respect to time course (data not shown). We carried out 
immunocytochemistry for endothelial cell markers in mEB cells from EGM-2 medium 
(Figure 3B), and observed capillary-like structures on day 10. These were stained with 
specific antibodies for FLK-1, PECAM and VE-Cadherin. The immunoreactivity of each 
marker was strong and was observed throughout EBs cells. 
In addition, we performed flow cytometry analysis for the expressions of FLK-1, PECAM, 
and VE-Cadherin with time (Figure 4). Cells which are positive for these markers were 
observed to increase with time. For cells grown in DMEM containing 10% FBS medium and 
EGM-2 medium for 10 days the percentages expressing these markers were; FLK-1 4.0% and 
5.3%, PECAM 10.9% and 44.5%, and VE-Cadherin 5.2% and 6.4%, respectively. These results 
demonstrate that the expressions of endothelial cell markers at the mRNA and protein levels 
were greater in cells grown in EGM-2 medium than in DMEM containing 10% FBS medium.  
 
 
Fig. 4. Kinetics of the expressions of FLK-1, PECAM and VE-cadherin during the 
differentiation of mES cells according to flow cytometric analysis. Numbers indicate the 
percentages of target antibody-positive cells 
5.2.2 Formation of capillary structures by differentiated mES cells on matrigel  
Mouse ES cells cultured in EGM-2 medium for 10 days differentiated into the endothelial 
cell lineage. Thus, we used gelatin coated dishes and a Matrigel system to confirm whether 
the mES cells cultured EGM-2 medium effectively construct capillary structures. We 
cultured mES derived endothelial cells in EGM-2 medium on gelatin coated dishes and 
Matrigel. After 5 days, we found that mES cells on the gelatin coated dishes could not 
construct capillary-like structures (Figure 5A), on the other hand, mES cells on Matrigel 
rapidly formed capillary-like structures, which resembled those formed by HUVEC and 
other endothelial cell populations (Figure 5B).  
www.intechopen.com
Application of Embryonic Stem Cells as a Novel Tool in Drug Screening 
 
441 
 
Fig. 5. Formation patterns of vascular-like structures of mES cells. Morphologies of mouse 
ES cell-derived endothelial cells on a gelatin-coated plate (A) and a matrigel-coated plate (B) 
(×100). Arrow indicates vascular-like structure derived from mouse ESCs 
5.2.3 Differentiated mouse ES cells were more sensitive than mouse endothelial cells 
(C166) to 5-Fluorouracil  
In the sensitivity to expose 5-FU in mouse ES cells, the respective concentrations of 5-FU for 
50% reduction (IC50) in early stage (day 3) and late stage (day 9) assays for 24hr were 126 uM 
and 7.9 uM, respectively (data not shown). This data suggests that the sensitivity of 
differentiated endothelial cells to toxicity of 5-FU are more sensitive than undifferentiated 
endothelial cells. In order to confirm the usefulness of the vasculogenesis model produced 
from differentiated mouse ESCs using EGM-2 medium, we performed vasculogenesis 
cytotoxicity assays, by treating cells with 5-fluorouracil, a strong inhibitor of vessel  
 
 
Fig. 6. Illustration of the effects of 5-Fluorouracil on the 72-hour survival of mouse 
embryonic stem cells and C166 mouse endothelial cells as determined by MTT assays (A). 
The inhibitory concentrations (IC50) of 5-Fluorouracil in mES cells and C166 cells were 0.72 
µM and 1.04 µM, respectively. The morphology and PECAM expression of mouse ES cells 
exposed to 5- Fluorouracil (1 µM) (B). The expression of PECAM was decreased by 5-
fluorouracil treatment in mouse ES cells 
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formation, to both mouse ES cells and C166 cells. Generally, the growth rates of mouse ES 
and C166 cells were inhibited in a dose-dependent manner by 5-fluorouracil (Figure 6A). 
However, the concentrations 5-fluorouracil that caused a 50% reduction in mouse ES and 
C166 cells were 0.72 and 1.04 uM, respectively. In addition, the expression of PECAM 
significantly decreased in mouse ES derived endothelial cells which are exposed 5-FU 
(Figure 6B). From these results, we confirm that differentiated mouse ES cells are sensitive to 
5-fluorouracil comparing traditional screening systems (C166) for cell toxicity, so that 
endothelial cells derived mES can use as an in vitro model for vasculogenesis and toxicity 
screening. 
5.2.4 Effect of 5-FU on the endothelial differentiation of cells derived from mouse ESCs    
To study the role of 5-FU in endothelial differentiation, mouse ESCs were differentiated into 
endothelial precursor cells and treated with 5-FU (10 µM). Oct-4 expression and cell viability 
were analysed. The expression of Oct-4 gradually decreased, with 100%, 90.6%, 81.3%, 50.5%  
 
 
Fig. 7. The expression of Oct4 and the cytotoxicity of 5-Fluorouracil in endothelial precursor 
cells, derived from mouse embryonic stem cells. The expression of Oct4 gradually decreased 
during endothelial differentiation (A). After inducing endothelial differentiation for 9 days 
with EGM-2 medium, the cells were exposed to 5-fluorouracil (10 µM) with/without 
probucol (50 µM) for 24 hrs. Analysis of the cell viability of the endothelial differentiated 
cells exposed to 5-fluorouracil were assessed by MTT assays (B). The experiments were 
performed in 3 independent runs (n = 6). Standard error bars are shown. Significance was 
tested by the student t-test (* p < 0.01). Numbers indicate the percentages of target antibody-
positive cells 
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expression on differentiation days 0, 4, 7, and 10, respectively (Figure 7A). In a previous 
study, we found that the percentage of PECAM expression increased by up to 44.5% in 
mouse ES-derived endothelial precursor cells, grown in EGM-2 medium for 10 days. There 
is a strong correlation between the decreased Oct-4 expression and increased PECAM 
expression during the endothelial differentiation of cells derived from mouse ESCs. Next, 
we examined the viability of endothelial precursor cells when they were exposed to 5-FU (10 
µM), using MTT assays. As shown in the supplemental data, cells exposed to various 
concentrations of 5-FU and probucol for 24 hours displayed a decrease in cell viability in a 
concentration dependent manner. The IC50 of 5-FU and the concentration of probucol 
needed to avoid affecting cell viability were 10 µM, 50 µM, respectively. The viability was 
significantly decreased to 49.8% of the control in the endothelial differentiated cells exposed 
to 5-FU (10 µM) for 24 hours. The viability was significantly recovered to 65.7% in cells 
exposed to 5-FU (10 µM) combined with probucol (50 µM) (P < 0.01) (Figure 7B). 
5.2.5 5-FU inhibits cell proliferation in endothelial differentiated cells derived from 
mouse ESCs. 
The morphology of mouse ES-derived endothelial precursor cells after treatment with the 
IC50 values of 5-FU (10 µM) for 24 hours was changed and detached, compared to the  
 
 
Fig. 8. Anti-proliferative affect of 5-fluorouracil in endothelial precursor cells. Morphology (A, 
top panel) and PCNA expression (A, bottom panel) of control and cells exposed to 5-
fluorouracil (10 µM) with/without probucol (50 µM) for 24hrs. Cell nuclei were stained with 
DAPI. The percentages of cells with PCNA expression were analysed by FACS (B). Numbers 
indicate the percentages of target antibody-positive cells. Original Magnification: × 40 for (A) 
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control cells which grew as confluent aggregates with rounded and polygonal cell 
morphology. However, probucol (50 µM) treatment to the 5-FU treatment groups for 24 
hours induced a morphology similar to that of the control cells (Figure 8A, top panel). In 
order to investigate the effects of 5-FU on the proliferation of endothelial precursor cells 
derived from mouse ESCs, PCNA expression was assessed by immunocytochemistry and 
FACS analysis. After inducing endothelial differentiation for 9 days, we observed that the 
endothelial precursor cells exposed to 5-FU (10 µM) for 24 hours had decreased PCNA 
expression, whilst the probucol (50 µM) treated group had recovered its PCNA expression 
(Figure 8A, bottom panel). These results correlated with the PCNA expression of the 
endothelial precursor cells exposed to 5-FU (47.7%), as shown by FACS analysis (Figure 8B). 
5.2.6 Expression of PECAM in endothelial differentiated cells is down-regulated by 5-FU  
To test whether the treatment of mouse ES-derived endothelial precursor cells with 5-FU 
can influence endothelial differentiation through expression of endothelial specific genes, 
the expression levels of PECAM were analysed by immunocytochemistry and RT-PCR. The 
expression of PECAM was dramatically decreased in the 5-FU treatment group, compared 
to the control group. However, the expression of PECAM was maintained in the probucol 
treatment group (Figure 9). These findings demonstrate that, in accordance with the 
morphological differentiation analysis, 5-FU decreases endothelial-specific mRNA levels 
and so inhibits the expression of genes involved in endothelial differentiation. 
 
 
 
Fig. 9. PECAM expression of endothelial precursor cells, derived from mouse embryonic 
stem cells. Expression of PECAM in control and cells exposed to 5-fluorouracil (10 µM) 
with/without probucol (50 µM) for 24hrs were analysed by immunocytochemistry. Cell 
nuclei were stained with DAPI (A). mRNA levels of PECAM and GAPDH were evaluated 
by RT-PCR (B). GAPDH used as internal standard. Original Magnification: × 40 for (A) 
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5.2.7 Gene profiling of mouse embryonic stem cells exposed to 5-FU using Microarray 
analysis 
In order to determine gene expression changes in cells exposed to 5-FU (10 µM), the RNA 
contained in both the control cells, and the cells exposed to 5-FU treatment for 24 hours at 
differentiation day 9 was collected. As shown a Fig. 4, a total of 11,668 genes out of 32,996 
 
 
Fig. 10. Gene expression profiling of endothelial precursor control and cells exposed to 5-
fluorouracil using microarray analysis. Hierarchical clustering analysis was conducted using 
control (n=5) and 5-FU treated samples (n=5). The black bars on right side of A illustrate the 
location of clusters shown. The dendrogram in B shows the samples identified as being in 
the cell cycle category, between control and 5-FU treated cells. The intensity of red and 
green colour is proportional to the relative up-regulation (red) or down-regulation (green) of 
gene expression in the differentiated samples, compared to that in the undifferentiated 
reference. Gene names and accession numbers are from Unigene 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) 
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cDNAs were selected as differentially expressed genes by the ANOVA test (p < 0.001). A 
hierarchical cluster analysis yielded major clusters in the 11,668 expressed genes (Figure 10). 
These gene expression patterns were classified into functional groups, based on their 
biological process as defined by the Gene Ontology (GO) annotation system. Most of the 
observed genes were related to physiological processes, including apoptosis, cell cycle, 
developmental processes, and signal transduction in all clusters (Table 2). These results 
suggest that 5-FU treatment affects the expression of numerous genes via the alteration of 
several processes. Notably, expression of 58 genes out of the 1,439 genes in the cell cycle 
category was modulated by more than 2-fold, between the control cells and endothelial 
differentiated cells exposed to 5-fluorouracil (data not shown). 
 
Function (Panther classcification system) Number 
Angiogenesis 4 
Apoptosis 30 
Cell adhesion 22 
Cell cycle 58 
Cell proliferation and differentiation 9 
Cell structure and motility 36 
Developmental processes 80 
Homeostasis 7 
Immunity and defence 45 
Signal transduction 126 
Cell adhesion molecule 20 
Cell junction protein 8 
The others 994/1439 
Table 2. Gene content list of the AB 1700 mouse chip 
5.2.8 5-FU induces arrest of G1/S phase in endothelial-like cells derived from mouse 
ESCs 
To confirm the effects of 5-fluorouracil (10 µM) with and without probucol (50 µM) in the 
cell cycle, the cell cycle distribution was analysed by flow cytometry (Figure 11). Generally, 
the frequencies of G0/G1 phase and S-phase were 62.7% and 33.5% in mouse ESCs, 
respectively. In contrast, mouse ES-derived endothelial precursor cells exposed to 5-FU (10 
µM) for 24 hours showed a decrease to 31.1% in G0/G1 phase and an increase to 60.6% in S 
phase. Treatment with 50 µM probucol for 24 hours showed 35.0% of cells in G0/G1 phase 
and 62.8% in S-phase (Figure 11A). These data suggest that 5-FU arrests cells at the G1/S 
phase boundary in endothelial precursor cells, derived from mouse ESCs. This was followed 
by decreased proliferation of mouse ES-derived endothelial precursor cells, similar to that 
reported previously with other cell types (Vittet et al., 1996).To determine whether the 
expression levels of cell cycle related proteins were changed, we analysed Cyclins, CKDs, 
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CKDIs, and p53 expression after treatment with 5-FU (10 µM), with and without probucol 
(50 µM), by Western blot analysis. The expression of Cyclin E, CDK2, p21WAF1/CIP1, and p53 
was up-regulated in ES-derived endothelial precursor cells exposed to 5-FU, compared to 
those in the control group and cells treated with 5-FU (10 µM) and probucol (50 µM) (Figure 
11B). Although the expression of cyclin D1 remained constant in control cells and mouse ES-
derived endothelial precursor cells exposed to 5-FU, they were remarkably decreased by 
probucol treatment. Otherwise, there were no differences in the expression of CKD4 and 
p27Kip1, the tumour suppressor and inhibitors of Cyclin E / CDK2 in mouse ES-derived 
endothelial precursor cells, according to 5-FU and probucol treatments (Figure 11B). From 
these results, we suggest that 5-FU might inhibit G1-related Cyclin/CDK activities through 
the augmentation of p21WAF1/CIP1 expression and by binding to cyclin D/CDK complexes. 
 
 
Fig. 11. Cell cycle arrest in endothelial precursor cells after 5-Fluorouracil exposure. DNA 
distribution histogram, using PI labelling (x-axis) and total number of cells in each channel (y-
axis) in control and cells treated with 5-fluorouracil (10µM) with/without probucol (50 µM) 
(A). Western blot analysis of the expression of G1/S phase-related Cyclins, CDKs, and CDKIs 
in control and cells exposed to 5-fluorouracil (10µM) with/without probucol (50 µM) (B) 
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6. Conclusion  
In toxicological research, the development of alternative in vitro toxicity screening systems 
to replace in vivo screening methods using animal experiments and conventional 
screening systems is important. Although applications using primary cells derived from 
rodent embryo or tissue-specific cell lines originating from humans have been tried, the 
validation of cytotoxicity during cellular biological processing must be improved in order 
to establish new and alternative in vitro screening methods, and to increase the efficiency 
of toxicological analysis through these methods (Tiffany-Castiglioni et al., 1999). So, 
toxicity screening using stem cells is highlighted as an alternative cell source for in vitro 
toxicity screening because of several limitations of traditional in vitro assays using 
primary cells or cell lines. For examples, they couldn’t demonstrating the biological 
process involved in a toxic response to xenobiotics comparing to in vivo toxicity testing 
using animal model. In comparison to in vivo studies, the screening system using 
embryonic stem cell is highly accurate at predicting cellular toxicity, and outperforms 
classical assays, such as, the fetal limb micromass and post-implantation whole rat 
embryos culture assays (Scholz et al., 1999).  
Embryonic stem cell testing (EST) using the EB system provides a useful tool for 
analyzing the embryotoxic effects of chemical compounds (Spielmann et al., 1997; Scholz 
et al., 1999; Huuskonen, 2005). Whole embryo culture showed the best concordance 
between in vivo classification and in vitro test results with 80% correct classifications 
versus 78% for EST and 71% for limb bud micromass. Moreover, strong embryotoxicants 
showed a predictivity of 100% in each of the test systems (Genschow et al., 2002). The 
powerful advantages of ESCs when they are applied to toxicology come as a result of their 
unique properties compared to primary cells: self-renewal, plasticity to generate various 
cells types, and that they are a readily available alternative source to replace primary cells. 
Therefore, stem cell based screening systems for toxicants offer a very promising 
technology; it is possible to obtain large numbers of cells for consistent analysis and the 
study at the different stages of differentiation. In addition, toxicity screenings using ESCs 
have been validated as a reliable source for in vitro developmental toxicology studies 
(Rohwedel et al., 2001).  
In the present study, we developed a vasculogenesis model for the effective 
differentiation of mES cells into the endothelial lineage using EGM-2 medium. In 
addition, the availability of differentiated mouse embryonic bodies was confirmed by 
examining vascular toxicity using 5-Fluorouracil. Since Hirashima and colleagues 
reported that mES cells are important for studies for murine development, several 
systems for mES cell differentiation have been reported (Hirashima et al., 1999; Feraud & 
Vittet, 2003; Davila et al., 2004; Wobus & Boheler, 2005). The majority of reports issued 
during the past decade have focused on murine ES cells derived embryoid body (EB) 
formation assays. Differentiation system using embryoid bodies that have the potential to 
generate various embryonic cell lineages spontaneously induce differentiation 
(Doetschman et al., 1985; Risau et al., 1988; Wang et al., 1992). These studies show that the 
differentiation of ES derived EBs is more effective than ES cells in studies of 
vasculogenesis alone (Risau et al., 1988; Wang et al., 1992; Vittet et al., 1996; Bloch et al., 
1997; Wartenberg et al., 1998; Hirashima et al., 1999). Many strategies have been used for 
endothelial differentiation, i.e., the suspension method (Risau et al., 1988; Wang et al., 
1992), a method using semisolid medium (Vittet et al., 1996), and ES cell aggregation by 
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the hanging drop method (Goumans et al., 1999). Vittet and colleagues confirmed that ES-
derived endothelial cells acquire cell-specific markers in a time-dependent manner after 
LIF removal, which suggests that endothelial markers are expressed in sequential steps, 
which closely resemble endothelial cell differentiation in vitro during embryonic 
development (Vittet et al., 1996). In the present study, when mEBs formed by the hanging 
drop method for 3 days were cultured in EGM-2 medium containing 5% FBS and 
cocktailed cytokines for 10 days, the mRNA expressions of endothelial markers were 
found to show patterns similar to Vittet’s groups. However, the expression levels of 
endothelial markers of PECAM by FACS analysis were higher in the early stage than 
reported by Vittet. In addition, the expression levels of these markers were maintained to 
day 10. Although the proliferation activity of mES cells cultured in EGM-2 medium was 
lower than that of cells cultured in DMEM containing 10% FBS, the differentiation activity 
of those grown in EGM-2 medium was higher. These results suggest that serum contained 
potent stimulators of cell growth, such as, amino acids, growth factors, vitamins, proteins, 
hormones, lipids, and minerals can affect both proliferation and differentiation. Of these 
components, albumin protein has been previously reported to stimulate the proliferation 
of cells and to suppress their differentiation (Ishida & Yamaguchi, 2004). Therefore, we 
suggested that factors that stimulate differentiation were more abundant in EGM-2 
medium than in DMEM medium containing 10% FBS.  
A tyrosine kinase receptor for VEGF (FLK-1) is the marker of the lateral plate mesoderm and 
the earliest differentiation marker of endothelial cells and blood cells (Eichmann et al., 1997). 
Thus, an early stage defined by FLK-1 and PECAM expression might reflect commitment 
towards the endothelial lineage. PECAM is a member of the immunoglobulin superfamily 
expressed by endothelial cells and a subset of hematopoietic cells in the adult organism 
(Watt et al., 1995; DeLisser et al., 1997). It also was recently reported that undifferentiated ES 
cells express PECAM (Vittet et al., 1996; Ling & Neben, 1997). Because ES cells resemble the 
inner cell mass of the blastocyst, this suggested that PECAM may be expressed 
embryonically earlier than the described post-implantation stages. From these results, we 
confirmed that undifferentiated ES cells express PECAM, and we showed for the first time 
that this early expression mirrors PECAM expression in the mouse blastocyst. PECAM is 
expressed continuously during ES cell differentiation and characterizes a population of cells 
that are PECAM+ but not part of patent blood vessels. These cells have a possible 
counterpart in vivo in the yolk sac mesodermal cells that express PECAM before blood island 
formation. These findings are consistent with the model that ES cell differentiation 
recapitulates yolk sac development. (Redick & Bautch, 1999). These results define PECAM as 
the first cell adhesion molecule to be ICM-specific and suggest a potential role for this 
molecule prior to vascular differentiation. (Robson et al., 2001). 
Otherwise, expression of VE-cadherin was observed in later maturation (Vittet et al., 
1996). VE-cadherin is expressed at the earliest stages (E7.5) of vascular development in the 
mesodermal cells of the yolk mesenchyme. At later embryonic stages, VE-cadherin 
expression is restricted to the peripheral layer of blood islands that gives rise to 
endothelial cells and to the endothelium of most vessel types (Breier et al., 1996). 
According to our data, the mRNA expressions of Flk-1, PECAM, and VE-cadherin in mES 
cells cultured in EGM-2 medium were detected on day 4, day 4, and day 7, respectively. 
These results are similar to those of previous reports (Vittet et al., 1996; Hirashima et al., 
1999; Magnusson et al., 2004). 
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Festag and their colleagues reported that the exposed six test compounds such as all-
trans-retinoic acid (RA), 5-FU, diphenylhydantoin (DPH), valproic acid (Val), saccharin 
(Sacch), and penicillin G (Pen G), with known embryotoxic potential could disturb 
differentiation potential of murine embryonic stem cell as well as inhibit the 
differentiation of ES cells into endothelial cells (Festag et al., 2007). Because the sensitivity 
of differentiated murine embryonic stem cells to 5-FU comparing to endothelial cell line 
did not mentioned, the guideline as a correct mathematic model would not applied to a 
different evaluation of the experiments. However, we demonstrate that the differentiation 
of mES cells into endothelial cells as a measure of 5-FU, which is an anti-angiogenesis 
chemical toxicity is more sensitive than mouse endothelial cells (C166). In addition, we 
confirmed that the sensitivity to 5-FU for in the processing of endothelial differentiation 
from mouse embryonic bodies. These results suggest that EGM-2 medium is suitable to 
differentiate the endothelial cells from mES cells. In addition, the differentiated 
endothelial cells derived mES cells were more sensitive to vascular toxicity testing than 
traditional method. This devised system could be used as a tool for understanding of 
mechanism of vasculogenesis and for the screening of mesodermal-derived target organs 
toxicant.  
Furthermore, we demonstrate that 5-fluorouracil, an anti-cancer drug, can induce 
cytotoxicity in endothelial differentiation of mouse ESCs via inhibition of processes 
involved in cell viability, proliferation, and the cell cycle. During the induction of 
endothelial differentiation in cells derived from mouse ESCs, the expression of 
mesodermal lineage-related genes was up-regulated at 7 days after differentiation using 
EBs, followed by the up-regulation of endoderm lineage related genes at 14 days (Heo et 
al., 2005). Based on these reports, we induced endothelial differentiation from mouse 
ESCs for 10 days using EGM-2 to maximise endothelial differentiation, and confirmed the 
expression patterns of Oct-4 and PECAM. The frequencies of cells undergoing endothelial 
differentiation gradually increased through subsequent differentiation days; the 
expression of Oct-4 was 50.5% at endothelial differentiation day 10. These findings show 
that the characteristics of cells at endothelial differentiation day 10 are similar to 
endothelial precursor cells and endothelial-like cells. Because of this, these models can be 
used to evaluate the cytotoxicity of 5-FU at different stages of endothelial differentiation.  
A number of anti-cancer agents have been implicated in vascular toxicity and their effects 
have been attributed to direct toxicity to the endothelium, such as the HUVEC and C166 
cell lines. 5-FU gives an increase in the permeability of endothelial monolayers, as well as 
inducing vascular collapse and tumour necrosis (Watts et al., 1997). 5-FU, as a cytostatic 
agent with a strong embryotoxic potential, is known to have an effect in rapidly 
proliferating cells (Parker & Cheng, 1990; Shimizu et al., 2001). These reports are well 
matched with our results. The cytotoxicity of 5-FU in mouse ESCs was relieved by the 
addition of probucol (50 µM), an antagonist of 5-FU. This prevented the endothelial injury 
usually caused by 5-FU, but the rate of recovery for damaged endothelial cells did not 
completely return to normal (Kita et al., 1987; Kaneko et al., 1996). 
In order to understand the biological mechanism of target cell specific toxicants, DNA 
microarrays have been used to analyse gene profiling, to show the alteration of gene 
expression (Gunji et al., 2004; Mori et al., 2007; Fumoto et al., 2008). However, studies of 
gene profiling and the mechanisms within ESCs exposed to special toxicants, including 5-
FU, are still rare. Thus, we analysed expression patterns of genes involved in inducing 
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endothelial differentiation, using a DNA microarray with untreated and 5-FU-treated 
cells. As shown in the DNA microarray data, a huge number of changes in gene 
expression were identified by 5-FU treatment. Among these changes, we focused on genes 
involved in the cell cycle, as our data indicated that 5-FU induces cell proliferation 
inhibition. In contrast to the somatic cell cycle, ESCs have a unique feature, an abbreviated 
cell cycle (Becker et al., 2006). This is thought to be controlled through an unusual 
mechanism of CDK regulation, followed by a very short period of cell cycle. This allows 
ESCs to preserve their unlimited differentiation potential (Stead et al., 2002). In ESCs, the 
expressions of cyclin D1 and Cyclin D3 are low, and Cyclin D2 is not expressed, 
moreover, the expression of CDK-4 and the CDK 4-associated kinase activity is also weak, 
compared to somatic cells (Burdon et al., 2002). These previous reports lacked a consensus 
with our data, which showed increased expression of CDK4 and Cyclin D1 during 
endothelial differentiation. This discrepancy might originate from the differences between 
cell sources.  
Until now, the mechanism that has been reported to explain the cell cycle arrest by 5-FU 
treatment is a G1/S phase arrest in cancer cell lines, induced by blocking DNA synthesis 
through the inhibition of thymidylate synthase (Pinedo & Peters, 1988). When damaged 
by 5-FU treatment, in addition, the expression of the tumour suppressor p53 is increased 
p53 has been identified as a participant in the DNA damage response, resulting in either 
cell cycle arrest or death. It activates and regulates the transcription of cell cycle arrest or 
apoptosis related genes (Lane, 1992). The expression of p21, which a member of the 
WAF1/CIP1 family, and activates CKI which works as a linker with the p53-dependent 
pathway is up-regulated (Gartel et al., 1998). Once activated, the p53 gene product works 
together with the p21 WAF1/CIP1 protein, and binds to the cyclin D-CDK4 and cyclin E-CDK2 
complexes to inhibit their kinase activities (el-Deiry et al., 1993; Sherr & Roberts, 1999). 
Finally, increased expression of p21WAF1/CIP1 and p53 is involved in the G1/S-phase arrest 
of the cell cycle. These reports are in accordance with our data. In addition, the probucol 
treatment in ESCs, which blocks the cell cycle arrest by 5-FU, appears to aid the repair of 
damaged cells. Taken together, 5-FU affects endothelial differentiation by decreasing cell 
viability, proliferation and differentiation, as well as inducing the G1/S phase arrest. 
These toxicity screening are capable to use the mouse ESC system, therefore, mouse ESCs 
might be a useful model to use as a tool for screening the cytotoxicity of new compounds. 
However, there are still obstacles to overcome in toxicity screening using ESCs. For 
example, they do not grow as well and are more difficult to maintain and expand than 
other cell types and the procedures for directing them to differentiate are limited until 
now. Although stem cells allow for optimal preclinical evaluation of compounds directly 
on “relevant” human cells prior to clinical testing, it is important because relatively little 
information is usually obtained during preclinical development procedures on the 
manner in which novel drugs act on human tissues. Therefore, we should develop new 
sources of stem cells could be alternative to the use of ESCs in drug screening.  
7. References  
Astori, G.; Soncin, S. Lo Cicero, V. Siclari, F. Surder, D. Turchetto, L. Soldati, G. & Moccetti, 
T. (2010). Bone marrow derived stem cells in regenerative medicine as advanced 
therapy medicinal products. Am J Transl Res 2. 3. 285-295, 1943-8141 (Electronic) 
www.intechopen.com
 Methodological Advances in the Culture, Manipulation and  
Utilization of Embryonic Stem Cells for Basic and Practical Applications 
 
452 
Becker, K.A.; Ghule, P.N. Therrien, J.A. Lian, J.B. Stein, J.L. van Wijnen, A.J. & Stein, G.S. 
(2006). Self-renewal of human embryonic stem cells is supported by a shortened G1 
cell cycle phase. J Cell Physiol 209. 3. 883-893, 0021-9541 (Print) 0021-9541 (Linking) 
Bloch, W.; Forsberg, E. Lentini, S. Brakebusch, C. Martin, K. Krell, H.W. Weidle, U.H. 
Addicks, K. & Fassler, R. (1997). Beta 1 integrin is essential for teratoma growth and 
angiogenesis. J Cell Biol 139. 1. 265-278, 0021-9525 (Print) 0021-9525 (Linking) 
Bourzac, C.; Smith, L.C. Vincent, P. Beauchamp, G. Lavoie, J.P. & Laverty, S. (2010). Isolation 
of equine bone marrow-derived mesenchymal stem cells: a comparison between 
three protocols. Equine Vet J 42. 6. 519-527, 0425-1644 (Print) 0425-1644 (Linking) 
Breier, G.; Breviario, F. Caveda, L. Berthier, R. Schnurch, H. Gotsch, U. Vestweber, D. Risau, 
W. & Dejana, E. (1996). Molecular cloning and expression of murine vascular 
endothelial-cadherin in early stage development of cardiovascular system. Blood 87. 
2. 630-641, 0006-4971 (Print) 0006-4971 (Linking) 
Bremer, S.; & Hartung, T. (2004). The use of embryonic stem cells for regulatory 
developmental toxicity testing in vitro--the current status of test development. Curr 
Pharm Des 10. 22. 2733-2747, 1381-6128 (Print) 1381-6128 (Linking) 
Burdon, T.; Smith, A. & Savatier, P. (2002). Signalling, cell cycle and pluripotency in 
embryonic stem cells. Trends Cell Biol 12. 9. 432-438, 0962-8924 (Print) 0962-8924 
(Linking) 
Chambers, I.; Colby, D. Robertson, M. Nichols, J. Lee, S. Tweedie, S. & Smith, A. (2003). 
Functional expression cloning of Nanog, a pluripotency sustaining factor in 
embryonic stem cells. Cell 113. 5. 643-655, 0092-8674 (Print) 0092-8674 (Linking) 
Davila, J.C.; Cezar, G.G. Thiede, M. Strom, S. Miki, T. & Trosko, J. (2004). Use and 
application of stem cells in toxicology. Toxicol Sci 79. 2. 214-223, 1096-6080 (Print) 
1094-2025 (Linking) 
Dejana, E.; Bazzoni, G. & Lampugnani, M.G. (1999). Vascular endothelial (VE)-cadherin: 
only an intercellular glue? Exp Cell Res 252. 1. 13-19, 0014-4827 (Print) 0014-4827 
(Linking) 
DeLisser, H.M.; Christofidou-Solomidou, M. Strieter, R.M. Burdick, M.D. Robinson, C.S. 
Wexler, R.S. Kerr, J.S. Garlanda, C. Merwin, J.R. Madri, J.A. & Albelda, S.M. (1997). 
Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151. 3. 
671-677, 0002-9440 (Print) 0002-9440 (Linking) 
Denham, M. & Dottori, M. (2009). Signals involved in neural differentiation of human 
embryonic stem cells. Neurosignals 17. 4. 234-241, 1424-8638 (Electronic) 1424-862X 
(Linking) 
Doetschman, T.C.; Eistetter, H. Katz, M. Schmidt, W. & Kemler, R. (1985). The in vitro 
development of blastocyst-derived embryonic stem cell lines: formation of visceral 
yolk sac, blood islands and myocardium. J Embryol Exp Morphol 87. 27-45, 0022-0752 
(Print) 0022-0752 (Linking) 
Duret, C.; Gerbal-Chaloin, S. Ramos, J. Fabre, J.M. Jacquet, E. Navarro, F. Blanc, P. Sa-
Cunha, A. Maurel, P. & Daujat-Chavanieu, M. (2007). Isolation, characterization, 
and differentiation to hepatocyte-like cells of nonparenchymal epithelial cells from 
adult human liver. Stem Cells 25. 7. 1779-1790, 1066-5099 (Print) 1066-5099 (Linking) 
www.intechopen.com
Application of Embryonic Stem Cells as a Novel Tool in Drug Screening 
 
453 
Eichmann, A.; Corbel, C. Nataf, V. Vaigot, P. Breant, C. & Le Douarin, N.M. (1997). Ligand-
dependent development of the endothelial and hemopoietic lineages from 
embryonic mesodermal cells expressing vascular endothelial growth factor receptor 
2. Proc Natl Acad Sci U S A 94. 10. 5141-5146, 0027-8424 (Print) 0027-8424 (Linking) 
El-Deiry, W.S.; Tokino, T. Velculescu, V.E. Levy, D.B. Parsons, R. Trent, J.M. Lin, D. Mercer, 
W.E. Kinzler, K.W. & Vogelstein, B. (1993). WAF1, a potential mediator of p53 
tumor suppression. Cell 75. 4. 817-825, 0092-8674 (Print) 0092-8674 (Linking) 
Evans, M.J. & Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from 
mouse embryos. Nature 292. 5819. 154-156, 0028-0836 (Print) 0028-0836 (Linking) 
Feraud, O. & Vittet, D. (2003). Murine embryonic stem cell in vitro differentiation: 
applications to the study of vascular development. Histol Histopathol 18. 1. 191-199, 
0213-3911 (Print) 0213-3911 (Linking) 
Festag, M.; Viertel, B. Steinberg, P. & Sehner, C. (2007). An in vitro embryotoxicity assay 
based on the disturbance of the differentiation of murine embryonic stem cells into 
endothelial cells. II. Testing of compounds. Toxicol In Vitro 21. 8. 1631-1640, 0887-
2333 (Print) 0887-2333 (Linking) 
Fuh, E. & Brinton, T.J. (2009). Bone marrow stem cells for the treatment of ischemic heart 
disease: a clinical trial review. J Cardiovasc Transl Res 2. 2. 202-218, 1937-5395 
(Electronic) 
Fumoto, S.; Shimokuni, T. Tanimoto, K. Hiyama, K. Otani, K. Ohtaki, M. Hihara, J. Yoshida, 
K. Hiyama, E. Noguchi, T. & Nishiyama, M. (2008). Selection of a novel drug-
response predictor in esophageal cancer: a novel screening method using 
microarray and identification of IFITM1 as a potent marker gene of CDDP 
response. Int J Oncol 32. 2. 413-423, 1019-6439 (Print) 1019-6439 (Linking) 
Gartel, A.L.; Goufman, E. Tevosian, S.G. Shih, H. Yee, A.S. & Tyner, A.L. (1998). Activation 
and repression of p21(WAF1/CIP1) transcription by RB binding proteins. Oncogene 
17. 26. 3463-3469, 0950-9232 (Print) 0950-9232 (Linking) 
Genschow, E.; Spielmann, H. Scholz, G. Seiler, A. Brown, N. Piersma, A. Brady, M. 
Clemann, N. Huuskonen, H. Paillard, F. Bremer, S. & Becker, K. (2002). The 
ECVAM international validation study on in vitro embryotoxicity tests: results of 
the definitive phase and evaluation of prediction models. European Centre for the 
Validation of Alternative Methods. Altern Lab Anim 30. 2. 151-176, 0261-1929 (Print) 
0261-1929 (Linking) 
Goumans, M.J.; Zwijsen, A. van Rooijen, M.A. Huylebroeck, D. Roelen, B.A. & Mummery, 
C.L. (1999). Transforming growth factor-beta signalling in extraembryonic 
mesoderm is required for yolk sac vasculogenesis in mice. Development 126. 16. 
3473-3483, 0950-1991 (Print) 0950-1991 (Linking) 
Gunji, W.; Kai, T. Takahashi, Y. Maki, Y. Kurihara, W. Utsugi, T. Fujimori, F. & Murakami, 
Y. (2004). Global analysis of the regulatory network structure of gene expression in 
Saccharomyces cerevisiae. DNA Res 11. 3. 163-177, 1340-2838 (Print) 1340-2838 
(Linking) 
Heo, J.; Lee, J.S. Chu, I.S. Takahama, Y. & Thorgeirsson, S.S. (2005). Spontaneous 
differentiation of mouse embryonic stem cells in vitro: characterization by global 
www.intechopen.com
 Methodological Advances in the Culture, Manipulation and  
Utilization of Embryonic Stem Cells for Basic and Practical Applications 
 
454 
gene expression profiles. Biochem Biophys Res Commun 332. 4. 1061-1069, 0006-291X 
(Print) 0006-291X (Linking) 
Heuer, J.; Bremer, S. Pohl, I. & Spielmann, H. (1993). Development of an in vitro 
embryotoxicity test using murine embryonic stem cell cultures. Toxicol In Vitro 7. 4. 
551-556, 0887-2333 (Print) 0887-2333 (Linking) 
Hirashima, M.; Kataoka, H. Nishikawa, S. & Matsuyoshi, N. (1999). Maturation of 
embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. 
Blood 93. 4. 1253-1263, 0006-4971 (Print) 0006-4971 (Linking) 
Huttmann, A.; Li, C.L. & Duhrsen, U. (2003). Bone marrow-derived stem cells and 
"plasticity". Ann Hematol 82. 10. 599-604, 0939-5555 (Print) 0939-5555 (Linking) 
Huuskonen, H. (2005). New models and molecular markers in evaluation of developmental 
toxicity. Toxicol Appl Pharmacol 207. 2 Suppl. 495-500, 1096-0333 (Electronic) 0041-
008X (Linking) 
Ishida, K. & Yamaguchi, M. (2004). Role of albumin in osteoblastic cells: enhancement of cell 
proliferation and suppression of alkaline phosphatase activity. Int J Mol Med 14. 6. 
1077-1081, 1107-3756 (Print) 1107-3756 (Linking) 
Kaneko, M.; Hayashi, J. Saito, I. & Miyasaka, N. (1996). Probucol downregulates E-selectin 
expression on cultured human vascular endothelial cells. Arterioscler Thromb Vasc 
Biol 16. 8. 1047-1051, 1079-5642 (Print) 1079-5642 (Linking) 
Kari, G.; Rodeck, U. & Dicker, A.P. (2007). Zebrafish: an emerging model system for human 
disease and drug discovery. Clin Pharmacol Ther 82. 1. 70-80, 0009-9236 (Print) 0009-
9236 (Linking) 
Kim, S. & von Recum, H. (2008). Endothelial stem cells and precursors for tissue 
engineering: cell source, differentiation, selection, and application. Tissue Eng Part B 
Rev 14. 1. 133-147, 1937-3368 (Print) 
Kim, S.K.; Kim, B.K. Shim, J.H. Gil, J.E. Yoon, Y.D. & Kim, J.H. (2006). Nonylphenol and 
octylphenol-induced apoptosis in human embryonic stem cells is related to Fas-Fas 
ligand pathway. Toxicol Sci 94. 2. 310-321, 1096-6080 (Print) 1094-2025 (Linking) 
Kita, T.; Nagano, Y. Yokode, M. Ishii, K. Kume, N. Ooshima, A. Yoshida, H. & Kawai, C. 
(1987). Probucol prevents the progression of atherosclerosis in Watanabe heritable 
hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl 
Acad Sci U S A 84. 16. 5928-5931, 0027-8424 (Print) 0027-8424 (Linking) 
Knasmuller, S.; Mersch-Sundermann, V. Kevekordes, S. Darroudi, F. Huber, W.W. Hoelzl, 
C. Bichler, J. & Majer, B.J. (2004). Use of human-derived liver cell lines for the 
detection of environmental and dietary genotoxicants; current state of knowledge. 
Toxicology 198. 1-3. 315-328, 0300-483X (Print) 0300-483X (Linking) 
Knight, A.; (2007). Systematic reviews of animal experiments demonstrate poor human 
clinical and toxicological utility. Altern Lab Anim 35. 6. 641-659, 0261-1929 (Print) 
0261-1929 (Linking) 
Kulkarni, J.S. & Khanna, A. (2006). Functional hepatocyte-like cells derived from mouse 
embryonic stem cells: a novel in vitro hepatotoxicity model for drug screening. 
Toxicol In Vitro 20. 6. 1014-1022, 0887-2333 (Print) 0887-2333 (Linking) 
Kuo, T.K.; Hung, S.P. Chuang, C.H. Chen, C.T. Shih, Y.R. Fang, S.C. Yang, V.W. & Lee, O.K. 
(2008). Stem cell therapy for liver disease: parameters governing the success of 
www.intechopen.com
Application of Embryonic Stem Cells as a Novel Tool in Drug Screening 
 
455 
using bone marrow mesenchymal stem cells. Gastroenterology 134. 7. 2111-2121, 
2121 e2111-2113, 1528-0012 (Electronic) 0016-5085 (Linking) 
Lane, D.P.; (1992). Cancer. p53, guardian of the genome. Nature 358. 6381. 15-16, 0028-0836 
(Print) 0028-0836 (Linking) 
Liebsch, M. & Spielmann, H. (2002). Currently available in vitro methods used in the 
regulatory toxicology. Toxicol Lett 127. 1-3. 127-134, 0378-4274 (Print) 0378-4274 
(Linking) 
Ling, V. & Neben, S. (1997). In vitro differentiation of embryonic stem cells: 
immunophenotypic analysis of cultured embryoid bodies. J Cell Physiol 171. 1. 104-
115, 0021-9541 (Print) 0021-9541 (Linking) 
Magnusson, P.; Rolny, C. Jakobsson, L. Wikner, C. Wu, Y. Hicklin, D.J. & Claesson-Welsh, L. 
(2004). Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in 
fibroblast growth factor receptor-1-deficient vascular stem cell development. J Cell 
Sci 117. Pt 8. 1513-1523, 0021-9533 (Print) 0021-9533 (Linking) 
Martin, G.R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in 
medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 78. 12. 
7634-7638, 0027-8424 (Print) 0027-8424 (Linking) 
Mills, J.B.; Rose, K.A. Sadagopan, N. Sahi, J. & de Morais, S.M. (2004). Induction of drug 
metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J 
Pharmacol Exp Ther 309. 1. 303-309, 0022-3565 (Print) 0022-3565 (Linking) 
Mori, N.; Glunde, K. Takagi, T. Raman, V. & Bhujwalla, Z.M. (2007). Choline kinase down-
regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res 67. 
23. 11284-11290, 1538-7445 (Electronic) 0008-5472 (Linking) 
Nichols, J.; Zevnik, B. Anastassiadis, K. Niwa, H. Klewe-Nebenius, D. Chambers, I. Scholer, 
H. & Smith, A. (1998). Formation of pluripotent stem cells in the mammalian 
embryo depends on the POU transcription factor Oct4. Cell 95. 3. 379-391, 0092-8674 
(Print) 0092-8674 (Linking) 
Niwa, H.; Burdon, T. Chambers, I. & Smith, A. (1998). Self-renewal of pluripotent embryonic 
stem cells is mediated via activation of STAT3. Genes Dev 12. 13. 2048-2060, 0890-
9369 (Print) 0890-9369 (Linking) 
Parker, W.B. & Cheng, Y.C. (1990). Metabolism and mechanism of action of 5-fluorouracil. 
Pharmacol Ther 48. 3. 381-395, 0163-7258 (Print) 0163-7258 (Linking) 
Pearson, R.M. (1986). In-vitro techniques: can they replace animal testing? Hum Reprod 1. 8. 
559-560, 0268-1161 (Print) 0268-1161 (Linking) 
Petersen, B.E.; Bowen, W.C. Patrene, K.D. Mars, W.M. Sullivan, A.K. Murase, N. Boggs, S.S. 
Greenberger, J.S. & Goff, J.P. (1999). Bone marrow as a potential source of hepatic 
oval cells. Science 284. 5417. 1168-1170, 0036-8075 (Print) 0036-8075 (Linking) 
Pinedo, H.M. & Peters, G.F. (1988). Fluorouracil: biochemistry and pharmacology. J Clin 
Oncol 6. 10. 1653-1664, 0732-183X (Print) 0732-183X (Linking) 
Ramalho-Santos, M.; Yoon, S. Matsuzaki, Y. Mulligan, R.C. & Melton, D.A. (2002). 
"Stemness": transcriptional profiling of embryonic and adult stem cells. Science 298. 
5593. 597-600, 1095-9203 (Electronic) 0036-8075 (Linking) 
Rashid, S.T.; Corbineau, S. Hannan, N. Marciniak, S.J. Miranda, E. Alexander, G. Huang-
Doran, I. Griffin, J. Ahrlund-Richter, L. Skepper, J. Semple, R. Weber, A. Lomas, 
www.intechopen.com
 Methodological Advances in the Culture, Manipulation and  
Utilization of Embryonic Stem Cells for Basic and Practical Applications 
 
456 
D.A. & Vallier, L. (2010). Modeling inherited metabolic disorders of the liver using 
human induced pluripotent stem cells. J Clin Invest 120. 9. 3127-3136, 1558-8238 
(Electronic) 0021-9738 (Linking) 
Redick, S.D.; & Bautch, V.L. (1999). Developmental platelet endothelial cell adhesion 
molecule expression suggests multiple roles for a vascular adhesion molecule. Am J 
Pathol 154. 4. 1137-1147, 0002-9440 (Print) 0002-9440 (Linking) 
Risau, W.; Sariola, H. Zerwes, H.G. Sasse, J. Ekblom, P. Kemler, R. & Doetschman, T. (1988). 
Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. 
Development 102. 3. 471-478, 0950-1991 (Print) 0950-1991 (Linking) 
Robson, P.; Stein, P. Zhou, B. Schultz, R.M. & Baldwin, H.S. (2001). Inner cell mass-specific 
expression of a cell adhesion molecule (PECAM-1/CD31) in the mouse blastocyst. 
Dev Biol 234. 2. 317-329, 0012-1606 (Print) 0012-1606 (Linking) 
Rohwedel, J.; Guan, K. Hegert, C. & Wobus, A.M. (2001). Embryonic stem cells as an in vitro 
model for mutagenicity, cytotoxicity and embryotoxicity studies: present state and 
future prospects. Toxicol In Vitro 15. 6. 741-753, 0887-2333 (Print) 0887-2333 
(Linking) 
Schnerch, A.; Cerdan, C. & Bhatia, M. (2010). Distinguishing between mouse and human 
pluripotent stem cell regulation: the best laid plans of mice and men. Stem Cells 28. 
3. 419-430, 1549-4918 (Electronic) 1066-5099 (Linking) 
Scholz, G.; Pohl, I. Genschow, E. Klemm, M. & Spielmann, H. (1999). Embryotoxicity 
screening using embryonic stem cells in vitro: correlation to in vivo teratogenicity. 
Cells Tissues Organs 165. 3-4. 203-211, 1422-6405 (Print) 1422-6405 (Linking) 
Seiler, A.; Visan, A. Buesen, R. Genschow, E. & Spielmann, H. (2004). Improvement of an in 
vitro stem cell assay for developmental toxicity: the use of molecular endpoints in 
the embryonic stem cell test. Reprod Toxicol 18. 2. 231-240, 0890-6238 (Print) 0890-
6238 (Linking) 
Sherr, C.J. & Roberts, J.M. (1999). CDK inhibitors: positive and negative regulators of G1-
phase progression. Genes Dev 13. 12. 1501-1512, 0890-9369 (Print) 0890-9369 
(Linking) 
Shimizu, N.; Aoyama, H. Hatakenaka, N. Kaneda, M. & Teramoto, S. (2001). An in vitro 
screening system for characterizing the cleft palate-inducing potential of chemicals 
and underlying mechanisms. Reprod Toxicol 15. 6. 665-672, 0890-6238 (Print) 0890-
6238 (Linking) 
Smith, A.G. (1992). Mouse embryo stem cells: their identification, propagation and 
manipulation. Semin Cell Biol 3. 6. 385-399, 1043-4682 (Print) 1043-4682 (Linking) 
Spielmann, H. (2009). The way forward in reproductive/developmental toxicity testing. 
Altern Lab Anim 37. 6. 641-656, 0261-1929 (Print) 0261-1929 (Linking) 
Spielmann, H.; Genschow, E. Scholz, G. Brown, N.A. Piersma, A.H. Brady, M. Clemann, N. 
Huuskonen, H. Paillard, F. Bremer, S. & Becker, K. (2001). Preliminary results of the 
ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 29. 
3. 301-303, 0261-1929 (Print) 0261-1929 (Linking) 
Spielmann, H.; Pohl, I. Doering, B. Liebsch, M. & Moldenhauer, F. (1997). The embryonic 
stem cell test, an in vitro embryotoxicity test using two permanent mouse cell lines: 
www.intechopen.com
Application of Embryonic Stem Cells as a Novel Tool in Drug Screening 
 
457 
3T3 fibroblasts and embryonic stem cells. In. Vitro. Toxicol. 10. 119-127, 0887-2333 
(Print) 1879-3177 (Linking) 
Stead, E.; White, J. Faast, R. Conn, S. Goldstone, S. Rathjen, J. Dhingra, U. Rathjen, P. Walker, 
D. & Dalton, S. (2002). Pluripotent cell division cycles are driven by ectopic Cdk2, 
cyclin A/E and E2F activities. Oncogene 21. 54. 8320-8333, 0950-9232 (Print) 0950-
9232 (Linking) 
Steele, C.E.; New, D.A. Ashford, A. & Copping, G.P. (1983). Teratogenic action of 
hypolipidemic agents: an in vitro study with postimplantation rat embryos. 
Teratology 28. 2. 229-236, 0040-3709 (Print) 0040-3709 (Linking) 
Thomson, J.A.; Itskovitz-Eldor, J. Shapiro, S.S. Waknitz, M.A. Swiergiel, J.J. Marshall, V.S. & 
Jones, J.M. (1998). Embryonic stem cell lines derived from human blastocysts. 
Science 282. 5391. 1145-1147, 0036-8075 (Print) 0036-8075 (Linking) 
Tiffany-Castiglioni, E.; Ehrich, M. Dees, L. Costa, L.G. Kodavanti, P.R. Lasley, S.M. 
Oortgiesen, M. & Durham, H.D. (1999). Bridging the gap between in vitro and in 
vivo models for neurotoxicology. Toxicol Sci 51. 2. 178-183, 1096-6080 (Print) 1094-
2025 (Linking) 
Vanparys, P. (2002). ECVAM and pharmaceuticals. Altern Lab Anim 30 Suppl 2. 221-223, 
0261-1929 (Print) 0261-1929 (Linking) 
Vittet, D.; Prandini, M.H. Berthier, R. Schweitzer, A. Martin-Sisteron, H. Uzan, G. & Dejana, 
E. (1996). Embryonic stem cells differentiate in vitro to endothelial cells through 
successive maturation steps. Blood 88. 9. 3424-3431, 0006-4971 (Print) 0006-4971 
(Linking) 
Wang, R.; Clark, R. & Bautch, V.L. (1992). Embryonic stem cell-derived cystic embryoid 
bodies form vascular channels: an in vitro model of blood vessel development. 
Development 114. 2. 303-316, 0950-1991 (Print) 0950-1991 (Linking) 
Wartenberg, M.; Gunther, J. Hescheler, J. & Sauer, H. (1998). The embryoid body as a novel 
in vitro assay system for antiangiogenic agents. Lab Invest 78. 10. 1301-1314, 0023-
6837 (Print) 0023-6837 (Linking) 
Watt, S.M.; Gschmeissner, S.E. & Bates, P.A. (1995). PECAM-1: its expression and function as 
a cell adhesion molecule on hemopoietic and endothelial cells. Leuk Lymphoma 17. 3-
4. 229-244, 1042-8194 (Print) 1026-8022 (Linking) 
Watts, M.E.; Woodcock, M. Arnold, S. & Chaplin, D.J. (1997). Effects of novel and 
conventional anti-cancer agents on human endothelial permeability: influence of 
tumour secreted factors. Anticancer Res 17. 1A. 71-75, 0250-7005 (Print) 0250-7005 
(Linking) 
Wobus, A.M. & Boheler, K.R. (2005). Embryonic stem cells: prospects for developmental 
biology and cell therapy. Physiol Rev 85. 2. 635-678, 0031-9333 (Print) 0031-9333 
(Linking) 
Xu, J.J.; Diaz, D. & O'Brien, P.J. (2004). Applications of cytotoxicity assays and pre-lethal 
mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol 
Interact 150. 1. 115-128, 0009-2797 (Print) 0009-2797 (Linking) 
Yamaguchi, T.P.; Dumont, D.J. Conlon, R.A. Breitman, M.L. & Rossant, J. (1993). flk-1, an flt-
related receptor tyrosine kinase is an early marker for endothelial cell precursors. 
Development 118. 2. 489-498, 0950-1991 (Print) 0950-1991 (Linking) 
www.intechopen.com
 Methodological Advances in the Culture, Manipulation and  
Utilization of Embryonic Stem Cells for Basic and Practical Applications 
 
458 
Ying, Q.L.; Stavridis, M. Griffiths, D. Li, M. & Smith, A. (2003). Conversion of embryonic 
stem cells into neuroectodermal precursors in adherent monoculture. Nat Biotechnol 
21. 2. 183-186, 1087-0156 (Print) 1087-0156 (Linking) 
Zagami, C.J.; Zusso, M. & Stifani, S. (2009). Runx transcription factors: lineage-specific 
regulators of neuronal precursor cell proliferation and post-mitotic neuron subtype 
development. J Cell Biochem 107. 6. 1063-1072, 1097-4644 (Electronic) 0730-2312 
(Linking) 
Zhang, H. & Wang, Z.Z. (2008). Mechanisms that mediate stem cell self-renewal and 
differentiation. J Cell Biochem 103. 3. 709-718, 1097-4644 (Electronic) 0730-2312 
(Linking) 
Zhou, B.; Liu, C. Wang, J. Lam, P.K. & Wu, R.S. (2006). Primary cultured cells as sensitive in 
vitro model for assessment of toxicants--comparison to hepatocytes and gill 
epithelia. Aquat Toxicol 80. 2. 109-118, 0166-445X (Print) 0166-445X (Linking) 
www.intechopen.com
Methodological Advances in the Culture, Manipulation and
Utilization of Embryonic Stem Cells for Basic and Practical
Applications
Edited by Prof. Craig Atwood
ISBN 978-953-307-197-8
Hard cover, 506 pages
Publisher InTech
Published online 26, April, 2011
Published in print edition April, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Pluripotent stem cells have the potential to revolutionise medicine, providing treatment options for a wide
range of diseases and conditions that currently lack therapies or cures. This book describes methodological
advances in the culture and manipulation of embryonic stem cells that will serve to bring this promise to
practice.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Gi Jin Kim (2011). Application of Embryonic Stem Cells as a Novel Tool in Drug Screening, Methodological
Advances in the Culture, Manipulation and Utilization of Embryonic Stem Cells for Basic and Practical
Applications, Prof. Craig Atwood (Ed.), ISBN: 978-953-307-197-8, InTech, Available from:
http://www.intechopen.com/books/methodological-advances-in-the-culture-manipulation-and-utilization-of-
embryonic-stem-cells-for-basic-and-practical-applications/application-of-embryonic-stem-cells-as-a-novel-tool-
in-drug-screening
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
